9 Meters Biopharma
- Company typePrivate
- Founded2012
- HeadquartersRaleigh, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
9 Meters Biopharma firmographics
Firmographics- Name
- 9 Meters Biopharma
- Legal name
- 9 Meters Biopharma
- Website
- https://9meters.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
9 Meters Biopharma industry classification
Industry- Product category
- Rare Disease Gastrointestinal Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Rare Gastroenterology & Hepatology Disorder Therapies (HLAIAIAL)
- akta.pro secondary industries
- Gastroenterology Specialty Pharmaceuticals (HLAIACAE), Nutrition & Malabsorption (Celiac/Short Bowel) (HLAKAEAI), Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)
Keywords
Where 9 Meters Biopharma is headquartered
LocationHeadquarters
- HQ city
- Raleigh
- HQ country
- United States
- HQ region
- North America
Markets served
9 Meters Biopharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Pharmaceutical Product Sales: Once approved, the company plans to commercialize Vurolenatide for short bowel syndrome patients, generating revenue through prescription drug sales.
Go-to-market motion1 record
Marketing channels1 record
9 Meters Biopharma product offering
Product offeringCore offering
9 Meters Biopharma is developing Vurolenatide, an investigational GLP-2 analog currently in Phase 3 clinical trials for the treatment of short bowel syndrome (SBS). The therapy is designed to improve intestinal absorption and reduce patient dependence on parenteral nutrition in individuals suffering from SBS, a rare and serious gastrointestinal condition.
Product overview
9 Meters Biopharma is a clinical-stage biopharmaceutical company. The company website (9meters.com) could not be analyzed as the source data contains only the technology news website 9meters.com, not the biopharma company's official website. Based on news sources only: 9 Meters Biopharma is developing Vurolenatide (a GLP-2 analog) for the treatment of short bowel syndrome, currently in Phase 3 clinical development.
Differentiator
Problem solved
Functional benefit
Products and services
- Vurolenatide
Quantifiable outcome
- Phase 3 clinical development for Vurolenatide in short bowel syndrome
Companies that use 9 Meters Biopharma
Customer profileSegments1 record
Ideal customer profiles1 record
9 Meters Biopharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
9 Meters Biopharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Takeda PharmaceuticalminorIn May 2024, Takeda Pharmaceutical partnered with patient community platform Inspire to gather real-world insights for improving short bowel syndrome care. While not a direct partnership with 9 Meters Biopharma, this indicates competitor activity in the SBS space.
Scale indicators3 records
Recent moves6 records
Expansion highlights4 records
9 Meters Biopharma competitors and assessment
Company assessmentDirect peers
- Takeda Pharmaceutical: Takeda markets teduglutide (Gattex/Revestive), the only approved GLP-2 analog for short bowel syndrome. Direct competitor and the established incumbent in the same therapeutic space 9 Meters is targeting with Vurolenatide.
- VectivBio (acquired by Ironwood Pharmaceuticals): VectivBio developed apraglutide, a next-generation GLP-2 analog for short bowel syndrome, and was acquired by Ironwood Pharmaceuticals. Direct competitor pursuing the same indication with a differentiated once-weekly dosing profile.
- Zealand Pharma: Zealand Pharma developed glepaglutide, a long-acting GLP-2 analog for short bowel syndrome. Direct competitor with a Phase 3-ready asset targeting the same patient population as Vurolenatide.
Emerging players
- Ardelyx: Ardelyx is a specialty GI biopharmaceutical company with approved therapies (e.g., tenapanor/Ibsrela) addressing gastrointestinal disorders. Comparable as a GI-focused commercial-stage biopharma with overlapping patient-adjacent disease areas.
- Travere Therapeutics: Travere Therapeutics develops therapies for rare diseases, including rare metabolic and GI-related disorders. Comparable as a small-cap rare disease commercial-stage biopharma with similar focus on orphan indications.
- Soleno Therapeutics: Soleno Therapeutics is a clinical-stage rare disease biopharma developing therapeutics for uncommon conditions. Comparable as a small-cap, late-stage clinical company focused on rare diseases with unmet need.
Broad incumbents
- Madrigal Pharmaceuticals: Madrigal Pharmaceuticals is a commercial-stage biopharma that successfully developed and launched resmetirom (Rezdiffra) for MASH. Comparable as a late-stage-to-commercial rare/specialty liver-metabolic disease biopharma with analogous approval pathway execution.
Others
- Albireo Pharma (Ipsen): Albireo developed odevixibat (Bylvay) for rare pediatric cholestatic liver diseases and was acquired by Ipsen. Comparable as a rare GI/hepatobiliary specialty biopharma acquired by a larger player, illustrating strategic exit pathways for clinical-stage rare disease companies.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks4 records
Key highlights5 records
Customer concentration
9 Meters Biopharma social profiles
Digital presence9 Meters Biopharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
9 Meters Biopharma leadership team
Management profileNumber of profiles
Profiles6 records
9 Meters Biopharma funding detail
Funding detailFunding overview
Funding rounds4 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
9 Meters Biopharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 9 Meters Biopharma
What does 9 Meters Biopharma do?
9 Meters Biopharma is developing Vurolenatide, an investigational GLP-2 analog currently in Phase 3 clinical trials for the treatment of short bowel syndrome (SBS). The therapy is designed to improve intestinal absorption and reduce patient dependence on parenteral nutrition in individuals suffering from SBS, a rare and serious gastrointestinal condition.
When was 9 Meters Biopharma founded?
9 Meters Biopharma was founded in 2012. It employs 1 to 10 people.
Where is 9 Meters Biopharma based?
9 Meters Biopharma is headquartered in Raleigh, United States, in the North America region.
How does 9 Meters Biopharma make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are 9 Meters Biopharma's main competitors?
Direct peers on record are Takeda Pharmaceutical, VectivBio (acquired by Ironwood Pharmaceuticals) and Zealand Pharma. Emerging players are Ardelyx, Travere Therapeutics and Soleno Therapeutics. Madrigal Pharmaceuticals is listed as a broad incumbent. Albireo Pharma (Ipsen) is listed as an others.
Does 9 Meters Biopharma have an API?
No public API is recorded for 9 Meters Biopharma.
What industry is 9 Meters Biopharma in?
9 Meters Biopharma's product category is Rare Disease Gastrointestinal Therapeutics. Its primary akta.pro industry code is HLAIAIAL, Rare Gastroenterology & Hepatology Disorder Therapies, with a secondary code of HLAIACAE, Gastroenterology Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.